United Kingdom - 01 Dec, 2025: The United States and the United Kingdom have reached a landmark agreement that will eliminate tariffs on British pharmaceutical products and medical technologies, marking a significant step toward strengthening transatlantic collaboration in life sciences.

Under the deal, the UK will increase the net price it pays for new US medicines by 25%, while in return securing zero-tariff access for UK-manufactured medicines, active pharmaceutical ingredients, and medical technologies. These products will now be exempt from Section 232 sectoral tariffs and any future Section 301 country tariffs, a move set to benefit both exporters and healthcare providers across the UK.

The agreement forms part of the wider UK–US Economic Prosperity Deal, making the UK the only country in the world to secure a 0% pharmaceutical tariff regime with the United States. The UK government says this achievement will safeguard the medicines supply chain and reinforce Britain’s status as a global leader in life sciences investment.

A major outcome of this deal is a revision to the value appraisal framework used by the National Institute for Health and Care Excellence (NICE). The widely used quality-adjusted life year threshold, currently £30,000, will rise to £35,000.

According to the UK government, this adjustment enables NICE to “keep pace with the commercial and economic environment in which pharmaceutical companies are operating today.” The updated framework will apply to all new medicines, including but not limited to US-origin drugs, though it will not impact the prices of existing treatments.

The government also confirmed that its increased investment around 25% more in innovative, safe and effective treatments, the first major uplift in over 20 years, will allow NICE to approve more breakthrough therapies that were previously rejected purely on cost-effectiveness grounds. This could include innovative cancer therapies, rare disease treatments, and advanced approaches to conditions historically difficult to treat. The new framework is expected to significantly broaden patient access to advanced medicines.

In a government press release, Science Minister Lord Vallance said:

“We are entering an era of preventions and cures, and this landmark deal will ensure British patients are among the first in the world to access them. This is a vital agreement that delivers two big benefits. It will help us get the best and most innovative treatments to patients across the UK quickly. And with a world-beating deal on US tariffs, it is a huge boost for our pharmaceutical industry—cementing the UK as the destination of choice for life sciences businesses to invest, innovate, and grow.”

The Association of the British Pharmaceutical Industry (ABPI) welcomed the agreement, emphasising that it will support improved access to breakthrough medicines for UK patients and strengthen the UK’s attractiveness as a global destination for investment.

This breakthrough comes after the two nations agreed in May to pursue “significantly preferential treatment outcomes on pharmaceuticals,” with the UK committing to improving the operating environment for pharma companies. It also resolves a major outstanding trade issue after the UK became the first country earlier this year to secure tariff relief in select industries.

The deal follows a separate EU–US trade agreement finalised in July, which capped tariffs on pharmaceutical exports and most other goods at 15%.